Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
aflibercept + FOLFIRI (Sanofi)
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
Aflibercept + FOLFIRI is a combination regimen used primarily as a second-line treatment for metastatic colorectal cancer (mCRC) in patients who have progressed after an oxaliplatin-based chemotherapy. Aflibercept is a recombinant fusion protein that acts as a decoy receptor for vascular endothelial growth factor A (VEGF-A), vascular endothelial growth factor B (VEGF-B), and placental growth factor (PlGF), thereby inhibiting angiogenesis by preventing these ligands from binding to their endogenous receptors on endothelial cells. This reduces tumor blood vessel formation and nutrient supply[3][4][5][6]. FOLFIRI is a chemotherapy regimen consisting of folinic acid (leucovorin), fluorouracil (5-FU), and irinotecan; it works by interfering with DNA synthesis in rapidly dividing cancer cells[1]. The addition of aflibercept to FOLFIRI has been shown to improve overall survival in mCRC compared to FOLFIRI alone[3][5].
- Brand names
- Zaltrap (for aflibercept)FOLFIRI (for the combination of fluorouracil, leucovorin, and irinotecan)
- Other names
- ziv-afliberceptfolinic acid, fluorouracil, and irinotecanleucovorin, 5-fluorouracil, and irinotecan
02
Targets
PGF (Placental Growth Factor)VEGFA (Vascular endothelial growth factor A)VEGFB (Vascular endothelial growth factor B)
Beyond the preview
Go deeper on aflibercept + FOLFIRI (Sanofi).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on aflibercept + FOLFIRI (Sanofi).